immunoglobulin G

Phase 3Small molecule

immunoglobulin G is one of 90 small molecule programs targeting Dystrophic epidermolysis bullosa. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dystrophic Epidermolysis BullosaActive, not recruiting

Autoimmune EncephalitisActive, not recruiting

ImmunodeficiencyActive, not recruiting

Septic ShockActive, not recruiting

Dystrophic Epidermolysis BullosaPhase 1/Phase 2

Active, not recruiting

Autoimmune EncephalitisPhase 2

Active, not recruiting

ImmunodeficiencyPhase 3

Active, not recruiting

Septic ShockPhase 3

Active, not recruiting

Competition

Competitive Landscape

296 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

Viread

Gilead

Phase 3

1 2

Retrovir

BBp Consulting, Inc

Phase 3

6 3

Prezista

WWim Janssens

Phase 3

2 4

Prevnar 13

Merck & Co.

Phase 3

2 5

Atripla

Gilead

Phase 3

3 6

FTC/TDF

Gilead

Phase 3

1 7

PPSV23

Merck & Co.

Phase 3

1 8

immunoglobulin G

CSL Behring

Phase 3

1 9

Stribild

Gilead

Phase 3

3 10

DTG/3TC

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Dystrophic Epidermolysis Bullosa

NCT06834035

Clinical

Trials by Indication[1]

Kawasaki Disease2 trials

Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease

Completed·GGreen Cross Corporation·Phase 4·NCT01524939·45 enrolled

Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease

Completed·GGreen Cross Corporation·Phase 4·NCT04003844·45 enrolled

Dystrophic epidermolysis bullosa1 trial

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Recruiting·MM. Peter Marinkovich·Phase 1/2·NCT06834035·8 enrolled

Septic Shock1 trial

GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock

Terminated·GGreen Cross Corporation·Phase 3·NCT01315496·214 enrolled

ESS1 trial

A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions

Completed· Roche logo

Roche·Phase 1·NCT07025577·82 enrolled

Autoimmune Encephalitis1 trial

Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:

Completed·GGreen Cross Corporation·Phase 2·NCT04175522·23 enrolled

2 more indications

Treatment1 trial

IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff

Terminated·UUniversity of Pittsburgh·Phase 4·NCT00177970·14 enrolled

Immunodeficiency1 trial

Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency

Completed· CSL Behring logo

CSL Behring·Phase 3·NCT00680446·41 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for immunoglobulin G. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — immunoglobulin G compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for immunoglobulin G. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CSL Behring

immunoglobulin G

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Kawasaki Disease2 trials

Dystrophic epidermolysis bullosa1 trial

Septic Shock1 trial

ESS1 trial

Autoimmune Encephalitis1 trial

Treatment1 trial

Immunodeficiency1 trial

References

Drug Info

Quick Facts

Related News